by Alberto Matteelli and Haileyesus Getahun
World Health Organization, 2015
The main objective of this update is to reassess the recommendation to provide Isoniazid Preventive Therapy (IPT) for 36 months to children and adults living with HIV, including pregnant women, those receiving antiretroviral therapy (ART), and those who have successfully completed TB treatment and are living in settings with high TB and HIV prevalence and transmission. In resource-constrained settings with high TB incidence and transmission, adults and adolescents living with HIV, who have an unknown or positive tuberculin skin test (TST) status and among whom active TB disease has been safely ruled out, should receive at least 36 months of IPT. IPT should be given to such individuals regardless of whether or not they are receiving ART. IPT should also be given irrespective of the degree of immunosuppression, history of previous TB treatment, and pregnancy.